Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 13/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522272 | 0.85 | TIPARP (1.00) | TIPARPPOLBALDH1A1 | |
| SCHEMBL21522308 | 0.85 | TIPARP (1.00) | TIPARPPOLBALDH1A1TRPC5 | |
| SCHEMBL25617430 | 0.84 | TIPARP (0.74) | TIPARPPOLBTRPC5 | |
| SCHEMBL21521884 | 0.84 | TIPARP (1.00) | TIPARPPOLBALDH1A1 | |
| SCHEMBL21521766 | 0.83 | TIPARP (0.71) | TIPARPPOLBALDH1A1TRPC5 | |
| SCHEMBL25617433 | 0.83 | TIPARP (0.72) | TIPARPPOLBALDH1A1TRPC5 | |
| SCHEMBL21521232 | 0.81 | TIPARP (0.68) | TIPARPALDH1A1TRPC5 | |
| SCHEMBL21521177 | 0.81 | TIPARP (1.00) | TIPARP | |
| SCHEMBL21521034 | 0.80 | TIPARP (1.00) | TIPARPPOLBALDH1A1 | |
| SCHEMBL8221645 | 0.79 | TIPARP (0.65) | TIPARPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-01-28 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2020-04-23 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024502-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-10550105-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-20190330194-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-11014913-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-10870641-B2 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
| US-20200123134-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | TIPARP 152/4885POLB 110/4885ALDH1A1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.